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ABSTRACT 
POLYMORPHISMS OF GLUTATHIONE S- TRANSFERASE GENES 
(GSTM1, GSTP1, AND GSTT1) AND BREAST CANCER SUSCEPTIBILITY 
IN THE TURKISH POPULATION 
 
 
Ebru  DEMİR 
Ms. in Molecular Biology and Genetics 
Supervisor: Asst.Prof.Dr.Işık G. YULUĞ 
August 2002, 98 pages 
 
 
The potential association between the Glutathione S- transferase genes 
GSTM1, GSTT1, GSTP1 and breast cancer susceptibility was investigated in a case 
control study of 264 female patients and 233 age-matched controls in the Turkish 
population. The combined GSTP1 105 Ile/Val or Val/Val genotypes was 
significantly associated with breast cancer risk in all women (odds ratio OR=1.64,  
95% confidence interval CI=1.09-2.47 and in premenopausal women is OR= 2.01, 
95% CI=1.06-3.83). Neither GSTM1 nor GSTT1 was found to be associated with 
breast cancer. Distribution of GSTP1 genotypes was stratified according to body 
mass index (BMI), age, age at menarche, age at full-term pregnancy, number of full-
term pregnancies, and family history of breast cancer. The association of the 
combined GSTP1 105 Ile/Val or Val/Val genotypes with breast cancer risk was 
further exacerbated in women with high BMI (OR=2.12, 95% CI=1.35-3.62), but not 
with a low BMI (OR=0.78, 95% CI=0.45-1.34). These findings support the role for 
the combined GSTP1 105 Ile/Val or Val/Val genotypes in the development of breast 
cancer, particularly with a high BMI. 
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ÖZET             
TÜRK TOPLUMUNDA GLUTATYON S-TRANSFERAZ GENLERİNİN (GSTM1, 
GSTT1,GSTP1) POLİMORFİZMLERİ VE MEME KANSERİ İLE İLİŞKİSİ 
 
 
Ebru DEMİR 
Moleküler Biyoloji ve Genetik Yüksek Lisansı 
Tez Yöneticisi: Yrd.Doç.Dr.Işık G. YULUĞ 
Ağustos 2002, 98 sayfa 
 
   
GSTM1, GSTT1 ve GSTP1 Glutatyon S-Transferaz genleri ile meme 
kanserine yatkınlık arasındaki olası ilişki Türk toplumunda 264 kadın hasta ve 233 
yaş bakımından eşleştirilmiş kontrol bireyinde incelendi. Kombine GSTP1 105 
Ile/Val veya Val/Val genotipleri tüm kadınlarda (olasılık oranı OR=1.64, %95 güven 
aralığı GA=1.09-2.47) ve premenopozal kadınlarda (OR=2.01, %95 GA=1.06-3.83) 
(belirgin şekilde artmış olarak) meme kanseri riskiyle ilişkiliydi. Ne GSTM1 ne de 
GSTT1 meme kanseri ile ilişkili bulunmadı. GSTP1 genotiplerinin dağılımı vücut 
kütle oranı (VKO), yaş, menarş yaşı, miyadında doğum yaşı, miyadında doğum 
sayısı ve ailede meme kanseri öyküsüne göre gruplandırıldı. Kombine GSTP1 105 
Ile/Val veya Val/Val genotiplerinin meme kanseri riski ile ilişkisi yüksek VKO’lu 
hastalarda (OR=2.12, %95 GA=1.35-3.62) daha da belirgindi, ama düşük VKO’lu 
hastalarda değildi (OR=0.78, %95 GA=0.45-1.34). Bu bulgular meme kanseri 
gelişiminde, özellikle yüksek VKO’lu kadınlarda kombine GSTP1 105 Ile/Val veya 
Val/Val genotiplerinin rolü olduğu düşüncesini desteklemektedir.    
 
 
 
 
 
 
 
 
 iv 
 
ACKNOWLEDGEMENTS 
 
 
 
 
I am grateful to my advisor Asst. Prof. Işık G. Yuluğ_ for her supervision, 
guidance, continuous support and being with me at all times.I also would like to 
thank Assoc.Prof.Tayfun Özçelik, for his motivating comments and helpful critisims. 
            Many thanks to Dr. Gökçe A. Törüner, and Dr. Dilek Güvenç for supporting 
me with their knowledge and experience. 
             I also thank Dr. Betul Bozkurt for providing the samples and the clinical data 
for my work. 
             I  would particularly like to thank all members of the MBG department for 
their support and friendship.  
             Many thanks to my family, especially my mother for always giving her 
unconditioned support and love. 
             I am very grateful to Sargun Tont, Atasay Kotanak and all my friends for 
their continuous support and encouragement and being there for me when I needed 
them the most. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 v 
 
Table of Contents 
 
 
SIGNATURE PAGE ……………………………………………………………… i 
ABSTRACT………………………………………………………………………... ii 
ÖZET......................................................................................................................... iii 
ACKNOWLEDGEMENTS……………………………………………………… iv 
TABLE OF CONTENTS…………………………………………………………... v 
LIST OF TABLES…………………………………………………………………. vii 
LIST OF FIGURES………………………………………………………………... viii 
ABBREVIATIONS……………………………………………………………….. ix 
 
1. Introduction…………………………………………………………………..… 1
  
1.1. Genetic Basis of Human cancer………………………………………….... 1 
1.1.1. Cancer and Related Genes……………………………………….… 1 
1.1.1.1.Genetic Events in Cancer, Gain-of-function…………….…..…. 1 
1.1.1.2.Genetic Events in Cancer, loss-of-function………………...….. 2 
1.1.1.3.Patterns of Tumorigenic Events………………………………... 2 
1.1.2. Inherited Predisposition……………………………………………. 4 
1.1.2.1.Strong Predisposition…………………………………………... 4 
1.1.2.2. Weak Predisposition…………………………………………... 7 
1.1.2.2.1. Glutathione S-Transferases (GST)……………………... 10
  
1.1.3. Genetic Events Outside the Cancer Pathway………………………. 14 
1.2. Breast Cancer……………………………………………………………… 31 
1.2.1. Clinical Information………………………………………………... 31 
1.2.1.1.Epidemiology and Etiology……………………………………. 31 
1.2.2. Genetic Predisposition to Breast Cancer…………………………… 32 
1.3. Aim………………………………………………………………………... 38 
2. Materials and Methods…………………………………………………………. 39
  
2.1. Materials…………………………………………………………………... 39
  
2.1.1. Subjects…………………………………………………………… 39 
2.1.1.1.Patients…………………………………………………………. 39 
2.1.1.2.Age-matched Control Group…………………………………… 41 
2.1.1.3.Random Control Group………………………………………… 41 
2.1.2. Oligonucleotides…………………………………………………… 41 
2.1.3. Chemical and Reagents…………………………………………….. 43 
2.1.4. PCR Materials……………………………………………………… 44 
2.1.5. Restriction Endonucleases………………………………...……….. 44 
2.1.6. Standard Solutions…………………………………………………. 44 
2.2. Methods…………………………………………………………………… 46 
2.2.1. DNA Isolation……………………………………………………… 46 
2.2.2. Polymerase Chain Reaction (PCR)………………………………… 47 
2.2.3. Restriction Endonuclease Digestion ………………………………. 47 
 vi 
2.2.4. Agarose Gel Electrophoresis……………………………………….. 47 
2.2.5. Genotyping of Individuals…………………………………………. 48 
2.2.5.1.GSTP1 Genotyping…………………………………………….. 48 
2.2.5.2.GSTT1 Genotyping…………………………………………….. 48 
2.2.5.3.GSTM1 Genotyping……………………………………………. 49
  
2.2.6. Statistical Analyses………………………………………………… 53
  
2.2.6.1.Chi-square Test………………………………………………… 53 
2.2.6.2.Odds Ratio Calculation………………………………………… 55 
2.2.6.3.Multivariate Adjusted Odds Ratio Calculation………………… 57 
2.2.6.4.Gene-environment, Gene-Gene Interaction Analyses…………. 57 
3. Results………………………………………………………………………….. 60 
4. Discussion……………………………………………………………………… 72 
5. Conclusion and Future Perspectives…………………………………………… 77 
6. References……………………………………………………………………… 78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii 
 
 
LIST OF TABLES: 
 
Table 1: List of Familial Cancer Genes and Syndromes…………………………... 6 
Table 2: Major gene polymorphisms associated with cancer……………………… 8 
Table 3: The association of GSTM1 null genotype and cancer in 
              case control studies……………………………………………………….. 14 
Table 4: The association of GSTP1 Ile 105 Val polymorphism and  
               cancer in case control studies…………………………………………….. 21 
Table 5: The association of GSTT1 null genotype and cancer in  
              case control studies……………………………………………………….. 24 
Table 6: Genetic association ( case control ) studies in breast cancer……………... 34 
Table 7. CYPs and breast cancer in women………………………………………... 37 
Table 8: Selected characteristics for breast cancer patients (n=264) and  
              age-matched control subjects (n=233)……………………………………. 40 
Table 9.  List of primers for gene specific amplification…………………………... 42 
Table 10. Sample 2x2 Table for OR analysis……………………………………… 56 
Table 11: Definition of ORs (OR01, OR10, OR11) and interaction parameters 
                (Ψ,Φ) for the relations of two dichotomous environmental and  
                genetic factors and cancer……………………………………………….. 59 
Table 12:Characteristics of participants in this study……………………………… 66 
Table 13. Distribution of the GSTM1, GSTP1 and GSTT1 genotypes in   
                the age matched controls and breast cancer patients……………………. 67 
Table 14: Distribution of GST genotypes stratified according to BMI in cases 
                and controls……………………………………………………………… 68 
Table 15: Combination of the GSTT1 null genotype with the  
                GSTP1 105 Ile/Val or Val/Val genotype for breast cancer risk………… 69 
Table 16: Combination of the GSTM1 null genotype with the   
                GSTP1 105 Ile/Val or Val/Val genotype for breast cancer risk…………. 70 
Table 17: Combination of the GSTT1 and GSTM1 null genotypes with  
                 the GSTP1 105 Ile/Val or Val/Val genotype for breast cancer risk……. 71 
 viii 
 
 
LIST OF FIGURES 
 
 
 
Figure 1. The cellular pathways in cancer…………………………………………. 3 
Figure 2: Overview of enzymatic detoxification……….………………………….. 11 
Figure 3: The glutathione S-tranferase super-gene family………………………… 11 
Figure 4: A framework for genetic events related to cancer development………… 30 
Figure 5: Schematic representation of GSTP1 ......................................................... 50 
Figure 6: Schematic representation of GSTT1........................................................... 51 
Figure 7: Schematic representation of GSTM1.......................................................... 52 
Figure 8. Genotyping of GSTM1 gene……………………………………………... 63 
Figure 9: Genotyping of GSTP1 gene……………………………………………… 64 
Figure 10: Genotyping of GSTT1 gene…………………………………………. 65 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ix 
 
ABBREVIATIONS 
 
 
APC Adenomatous Polyposis of the Colon 
BRCA1 Breast Cancer Susceptibility Gene 1 
BRCA2 Breast Cancer Susceptibility Gene 2 
CASP10 Caspase 10 
CDH1 Cadherin 1 
CDKN1C Cyclin dependent kinase 1C 
CDKN2A Cylin Dependent kinase 2A 
CI Confidence Interval 
CYP1A1 Cytochrome P450 1A1  
CYP1A2 Cytochrome P450 1A2 
CYP1B1 Cytochrome P450 1B1 
CYP2A6 Cytochrome P450 2A6 
CYP2C19 Cytochrome P450 2C19 
CYP2D6 Cytochrome P450 2D6 
CYP3A4 Cytochrome P450 3A4 
CYP11a Cytochrome P450, subfamily Xia 
CYP17 Cytochrome P450, subfamily XVII 
CYP19 Cytochrome P450, subfamily XIX 
DNA Deoxyribonucleic acid 
DIA4 Diaphorase 4 
dNTP Deoxynucleotide triphosphate 
ERCC1 Excision repair cross-complementing rodent 
deficiency  complementation group 1 
ERCC2 Excision repair cross-complementing rodent 
deficiency complementation group 2 
ESRRA  Estrogen-related receptor alpha 
EXT1  Exostosin 1 
EXT1  Exostosin 1 
GSTM1  Glutathione S-Transferase mu 1 
GSTM2  Glutathione S-Transferase mu 2 
GSTM3  Glutathione S-Transferase mu 3 
 x 
GSTM4  Glutathione S-Transferase mu 4 
GSTM5  Glutathione S-Transferase mu 5 
MADH4  Mothers against decapapenaplegic Drosophila 
    Homolog of 4 
MEN1  Multiple Endocrine Neoplasia type1 
MLH1  Mut L Homolog 1 
ml milliliter 
mM milimolar 
µl microliter 
MPO Myeloperoxidase 
MSH2 Mut S Homolog 2 
NAT1 N-Acetyl Trransferase Type 1 
NAT2 N-Acetyl Transferase Type 2 
NF1 Neurofibromatosis 1 
NF2 Neurofibromatosis 2 
ng nanogram 
OR odds ratio 
pmol picomol 
PPARA Peroxisome Proliferative Activated Receptor, Alpha 
PPARG Peroxisome Proliferative Activated Receptor,Gamma 
PRKAR1A Protein kinase,c-AMP dependent regulatory,type 1 
POLB Polymerase Beta 
PTGS1 Prostaglandin-Endoperoxide Synthase 1 
PTGS2 Prostaglandin-EndoperoxideSynthase 2 
RB Retinoblastoma gene 
RET Rearranged during Transfection 
SDHD Succinate Dehydrogenase Complex, Subunit D 
SMARCB1 SWI/SNF-related, Matrix-Associated, 
  Actin-Dependent regulator of chromatin 
Subfamily1, Member 1 
SULT1A1 Sulphotransferase 1A1 
SULT1A2 Sulphotransferase 1A2 
TNF Tumor Necrosing Factor 
TP53 Tumor Protein p53 
 xi 
TSC1 Tuberous Sclerosis 1 
TSC2 Tuberous Sclerosis 2 
VDR Vitamin D Receptor 
VHL Von Hipple-Lindau 
XRCC1 X-ray repair complementing defective repair in 
Chinese hamster cells 1 
X2 Chi-square 
WT1 Wilm’s Tumor 1 gene 
 
 1 
1. Introduction 
1.1     Genetic Basis of Human Cancer 
 
All cancers are caused by abnormalities in DNA sequence. Throughout life, 
the DNA in human cells is exposed to mutagens which causes errors in replication. 
This process results in  progressive, subtle changes in the DNA sequence of each cell 
(Futreal PA. et al. 2001). Occasionally, one of these somatic mutations alters the 
function of a critical gene, providing a growth advantage to the cell in which it has 
occurred and resulting in the emergence of an expanded clone derived from this cell. 
Additional mutations in the relevant target genes and consequent waves of clonal 
expansion produce cells that invade surrounding tissues and metastasize. Cancer is 
the most common genetic disease: one in three people in the western world develop 
cancer, and one in five die from it (Higgison J. et al 1992). 
 Self-sufficiency in growth signals, insensitivity to growth-inhibitory (anti-
growth) signals, evasion of programmed cell death (apoptosis), limitless replicative 
potential, sustained angiogenesis, and tissue invasion and metastasis are six 
capabilities that are shared in common by almost all types of human tumors 
(Hanahan D. and Weinberg AR. 2000). 
  
1.1.1    Cancer and Related Genes 
  
 Initiation and progression of cancer and the major genes, which take part in 
these processes, are shown in Figure 1. 
 
1.1.1.1.  Genetic Events in Cancer, Gain-of-function  
 
Oncogenes are altered forms of normal cellular genes called proto-oncogenes. 
In human cancers, proto-oncogenes are frequently located adjacent to chromosomal 
breakpoints and are targets for mutation. The products of proto-oncogenes regulate 
several events of cell cycle, cell division and differentiation. In a cancer cell, one or 
more of the components of these pathways are altered. Oncogenes exhibit a dominant 
phenotype at the cellular level and gain-of-function occurs when one copy of an 
oncogene is activated. Oncogenes may be transmitted from generation to generation 
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when the proto-oncogene mutates in the germ-line. A good example of an oncogene 
is ERBB2, which codes for a receptor for epidermal growth factor and is involved in 
glioblastoma, brain cancer and breast cancer. Another example is Bcl-1 coding for 
cyclin D1, which is a component of the cell cycle clock and is involved in breast, 
head and neck cancers. Other examples include C-Myc, N-Myc and L-Myc which are 
transcription factors that activate growth promoting genes and are involved in 
leukemia, neuroblastoma, and breast, lung and stomach cancers.  
 
1.1.1.2  Genetic Events in Cancer, Loss-of-function  
 
 Tumor suppressor genes encode proteins that function in growth regulatory or 
differentiation pathways and if altered contribute to cancer formation. Tumor 
supressor genes exhibit a recessive phenotype and require inactivation of both 
alleles. They are divided into two categories: Gatekeepers and Caretakers (Kinzler 
KW. and Vogelstein B. 1997). Genes whose mutation or altered expression distrupts 
the cell-cyle control and cell division, death or lifespan, promoting the outgrowth of 
cancer cells (e.g. Rb) are termed `Gatekeepers` and those whose change causes 
genomic instability, increasing the frequency of alteration in gatekeeper genes are 
defined as  `Caretakers` (e.g. MLH1, BRCA1). 
 
1.1.1.3  Patterns of Tumorigenic Events 
 
 Four to seven rate-limiting genetic events are needed for the development of 
the common epithelial cancers (Renan MJ. et al. 1993). The precise pattern of 
genetic alteration differs between cancers of different types and even of the same 
type. However, the patterns are not random (Liotta L. et al. 2000 and Suzuki S. et al. 
2000). The molecular profiling of tumors by genomic alterations or expression 
changes will reflect the possible mechanisms of tumor evolution, which may provide 
information of clinical value.  
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Figure 1. The cellular pathways in cancer (Adopted from Evan GI. and Vousden KH 
2001). 
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1.1.2  Inherited Predisposition 
 
 Genetic factors are involved in varying degrees in carcinogenesis. Germ-line 
mutations in BRCA1 or BRCA2 genes confer a high breast cancer risk to the 
individual; however, such strong predispositions are rare in a population. At the other 
end of the spectrum are the weak genetic effects (predisposition without evident 
family-history) that confer a low risk to the individual, even though they may be 
common in a population. 
 
1.1.2.1 Strong Predisposition  
 
 Familial adenomatous polyposis was described at the beginning of 20th 
century.  At that time hereditary cancer syndromes were thought to be very rare until 
a case-control study showed that a positive family history of stomach or colon cancer 
meant a three-fold increased risk for those cancers in family members (Brose MS et 
al. 2000). 
In 1960’s, family studies suggested an autosomal dominant mode of genetic 
transmission of certain clusters of carcinoma of the breast, ovary and colon (Brose 
MS et al. 2000). In the 1980’s, the gene for familial adenomatous polyposis was 
linked to 5q and then mapped to 5q21 (Brose MS et al. 2000). There are now more 
then 40 germ-line mutations known to be responsible for cancer susceptibility (Table 
1). 
 With the notable exception of RET oncogene, the germ-line mutations in 
hereditary cancers are usually on the tumor suppressor genes which are responsible 
for regulation of cell cycle and DNA repair. When the entire human genome 
mapping is completed, more cancer susceptibility genes may be found. The 
researchers will not be able to match so many genes to hereditary disorders without 
examining family histories.  
General features of hereditary cancer syndromes include the following:  
 
  Vertical transmission of cancer predisposition. This refers to the presence 
of a genetic predisposition in sequential generations. To have the cancer 
predisposition a person must inherit it from a parent. 
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   The mutant gene can be passed on to both male and female children. In 
the case of breast cancer, the women are at higher risk. Males develop 
breast cancer rarely. A male who inherits a cancer predisposition and 
shows no evidence of it can pass the altered gene on to his children. 
   When a parent carries an autosomal dominant predisposition, each child 
has a 50% chance of inheriting the predisposition. 
    Clinical characteristics. Patients with an autosomal dominant 
predisposition are diagnosed at an earlier age than in sporadic cases. Most 
known mutations that increase breast cancer risk also increase risk of 
ovarian cancer. In addition, two or more primary cancers such as multiple 
primary cancers of the same type (e.g. bilateral breast cancer) or primary 
cancers of different types (e.g. breast and ovarian cancer) can occur in the 
same individual.   
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Table 1: List of Familial Cancer Genes and Syndromes 
 
Gene Cancer syndrome 
APC Familial polyposis of colon 
BRCA1 Hereditary Breast/Ovarian Cancer 
BRCA2 Hereditary Breast/Ovarian Cancer 
CDH1 Familial gastric carcinoma 
CDKN2A Cutaneous malignant melanoma 
CDKN1C Beckwith-Wiedeman Syndrome 
CYLD Familial cylindramotosis 
EXT1 Multiple exostoses type 1 
EXT2 Multiple exostoses type 2 
MADH4 Juvenile Polyposis 
MEN1 Multiple endocrine neoplasia type1 
MLH1 Hereditary non-polyposis colon cancer 
MSH2 Hereditary non-polyposis colon cancer 
NF1 Neurofibromatosis type 1 
NF2 Neurofibromatosis type 2 
PRKAR1A Carney Complex 
PTCH Nevoid basal cell carcinoma 
PTEN Cowdens` Syndrome 
RB1 Familial Retinoblastoma 
RET Multiple endocrine neoplasia MEN2A, MEN2B 
and medullary thyroid carcinoma  
SDHD Familial paraganglioma 
SMARCB1 Rhabdoid predisposition syndrome 
TP53 Li-Fraumeni Syndrome 
TSC1 Tuberous Sclerosis 1 
TSC2 Tuberous Sclerosis 1 
STK11 Peutz-Jegers Syndrome 
VHL Von Hipple-Lindau Syndrome 
WT1 Familial Wilms` Tumor 
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1.1.2.2  Weak Predisposition 
 
 Weak predisposition to cancer may result from genetic variations in cancer 
pathways and low penetrance genes. Subtle sequence variants or polymorphisms may 
be associated with a small to moderately increased risk for cancer. In sporadic 
cancers, such factors affecting the probability of the events are very important.  Low 
penetrance gene candidates are found in many pathways such as environmental 
carcinogen detoxification, steroid hormone metabolism and DNA damage repair. 
However, polymorphisms in the genes regulating immune response, hormone 
regulation and apoptosis are also regarded as important genetic factors (Table 2) 
(Brockmoller J. et al. 2000). Identification of these genes will be greatly accelerated 
by the data from the Human Genome Project (Chakravarti A. 2001). 
  The search for candidate genes relies on cataloguing the DNA sequence 
variation within the population and showing that particular variants are significantly 
associated either with disease susceptibility or with some other aspects of the disease 
phenotype such as treatment response or survival (Cardon LR. and Bell JI. 2001). 
The most readily assayed form of genomic variation is a single nucleotide 
polymorphism (SNP). 2,84 million SNPs have been identified so far and are 
available from genomic databases (The Interval SNP Map Working Group, 2001). 
Although SNPs are mostly biallelic and less informative than microsatellite markers, 
they are more stable mutations. This enables more suitable association studies in 
which linkage disequilibrium (LD) between markers and an unknown variant is used 
to map disease-causing mutations. Since SNPs have only two alleles, which can be 
genotyped by a simple assay, this makes them more suitable to automated analysis. 
When identifying genes involved in determining complex traits, association studies 
are better suited for detecting genetic effects of low penetrance with higher 
resolution. For such studies, many more markers will be required in addition to better 
statistical tools and high-throughput low-cost genotyping technology to analyze large 
marker sets in many samples. The performance of numerous analyses on the small 
surface of oligonucleotide micro-arrays is one of the most promising approaches for 
large-scale SNP genotyping (Tillib SV. et al 2001) 
 8 
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1.1.2.2.1 Glutathione S-Transferases (GSTs) 
 
 Living organisms are continuously exposed to non-nutritional foreign 
chemical species. These xenobiotics may harm the organism, causing toxic and 
sometimes carcinogenic effects. Naturally occurring toxic compounds include plant 
and fungal toxins (e.g. plant phenols and aflatoxins) and reactive oxygen species 
(e.g. the superoxide radical and hydrogen peroxide). The enzymatic detoxification of 
xenobiotics such as polycyclic aromatic hydrocarbons (PAH) has been classified into 
three distinct phases. Phase I and II involve the conversion of a lipophilic, non-polar 
xenobiotic into a more water-soluble and therefore less toxic metabolite, which can 
then be eliminated more easily from the cell (phase III) (Figure 2).  
 Phase I is catalyzed mainly by the cytochrome P450 system. Phase II 
enzymes catalyze the conjugation of activated xenobiotics to endogenous water-
soluble substrates, such as reduced glutathione (GSH), UDP-glucuronic acid or 
glycine. In many species, conjugation to reduced glutathione catalyzed by GSTs is 
the major phase II reaction. GSTs can catalyze reactions resulting in the formation of 
GSH conjugates such as Micheal addition reactions which involve the addition of an 
enolate ion in a conjugate fashion to α, β-unsaturated ketones, nucleophilic aromatic 
substitutions, and epoxide ring-opening reactions. The reduction of hydroperoxides is 
also catalyzed by GSTs and results in the formation of oxidized glutathione (GSSG) 
(Hayes JD. and McLellan LI. 1999). 
 The GSH-xenobiotic conjugate is too hydrophilic to diffuse freely from the 
cell and must be pumped out actively by a transmembrane ATPase such as the GS-X 
pump (Ishikawa T. 1992) (Figure 2). 
 GSTs are dimeric and mainly cytosolic. In addition to their catalytic role in 
detoxification, they have extensive ligand binding properties (Barycki JJ. and 
Colman RF. 1997). Quite distinct from the cytosolic enzymes, a separate microsomal 
class of GSTs exists. The microsomal class of GSTs is designated as `membrane-
associated protein in eicosanoid and glutathione` metabolism (MAPEG) (Jakobsson 
PJ. et al 1999). 
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Figure 2: Overview of enzymatic detoxification (adopted from Sheehan D. et al. 
2001) 
 The GSTs comprise a complex and widespread enzyme super-family that has 
been subdivided into a number of classes by the amino acid/nucleotide sequence, and 
immunological kinetic and tertiary/quaternary structural properties. Human GSTs are 
a family of isozymes that includes at least eight distinct classes: alpha (A), mu (M), 
pi (P), sigma (S), theta (T), kappa (K), zeta (Z), and omega (O) (Strange CR. et al. 
2001) (Figure3). 
 
                        
alpha mu theta pi zeta sigma kappa omega
ancesteral GST gene
 
Chromosome   6p 1p 22q 11q 14q 4q ND 10q 
Genes A1-A4 M1-M5 T1,T2 P1 Z1 S1 K1 O1 
Allelic  yes  yes yes yes yes ? ? ?  
 
Figure 3: The glutathione S-tranferase super-gene family (Adopted from Strange CR 
et al. 2001).  
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 Several enzymes have been recognized as belonging to the Alpha and Mu 
classes. While the Pi class originally contained only one protein, GSTP1, at least five 
distinct Mu-class subunits (M1, M2, M3, M4 and M5) have been identified in 
humans with homologous gene loci (Strange CR et al. 2001). 
 Alpha-class GSTs comprises 4 types of subunits (A1, A2, A3, and A4) with 
homologous gene loci in humans. The identification of subgroups within the Alpha 
class was carried out by comparison of substrate preferences and sequence 
similarities. The A4 subunit has particularly high activity with ethacrynic acid, lipid 
hydroperoxides, and 4-hydroxyalkenals (Hubatsch I. et al. 1998). 
  GSTP1 is involved in the detoxification of base propenals (Norppa H. 1997), 
and metabolizes carcinogenic products such as benzo-(a)-pyrene dial epoxide, and 
acrolein, which are derived from cigarette smoke (Seidegard J. and Ekstrom G.1997). 
 Theta-class enzymes have unique substrate specificity in that they lack 
activity with 1-chloro-2,4-dinitrobenzene (CDNB), the `universal` GST substrate. 
Two distinct homodimers (GST1-1 and GST2-2) have been identified in humans with 
the T1 and T2 subunits (Pemble SE. et al 1994, and Schroder KR. et al 1996). 
 Human GSTP1-l has been shown to catalyze the isomerization of 13-cis-
retinoic acid to all-trans-retinoic acid (Chen H, and Juchau MR 1998). This is an 
example of an endogenous non-detoxification function for GSTs. In addition to their 
isomerization and GSH-conjugation activities, these enzymes contribute to defense 
against oxidative stress by their role as inhibitors of the Jun N-terminal kinase (Pi 
class) and their role in selenium-independent GSH peroxidase activities (Alpha class) 
(Zhao TJ. et al. 1998). These activities protects cells against the harmful effects of 
hydrogen peroxide including cell death (Adler V. et al 1999, and Yin Z. et al 2000).  
 GSTT1 detoxifies oxidative products of lipids and DNA. GSTT2 catalyzes 
cumene hydroxyoperoxidease (Norpha H. 1997). GSTT1 enzymes are also involved 
in the metabolism of carcinogenic substrates, such as methylating agents, pesticides 
and industrial solvents (Sheehan D. et al 2001). 
 Zeta-class is classified in the theta category (Miller MC. et al 2001). 
 Omega class enzyme shows high activity with CDNB (7-chloro-4- 
nitrobenzo-2-oxa-1, 3-diazole), p-nitrophenyl acetate and thiol transferase (Sheehan 
D. et al 2001). Omega class GSTs may act as a GSH-dependent thiol transferase 
removing S-thiol adducts which some proteins form with GSH and cysteine in 
response to oxidative stress (Board PG. et al. 2000). A novel possible role for Omega 
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class GSTs is protecting cells form apoptosis induced by Ca2+ mobilization from 
intracellular stores (Dulhunty A. et al 2001).  
 Polymorphisms in thee genes coding for enzymes involved in protection 
against oxidative stress have been implicated in predisposition to cancer (Forsberg L. 
et al. 2001). 
 It is obvious that the activity of GSTs is highly critical in the detoxification of 
carcinogens. Alterations in the structure, function or level of expression of GST 
genes or polymorphisms could alter the ability of the cell to inactivate carcinogens 
and mutagenes, thereby modifying cancer risk. The GSTM1 and the GSTT1 genes 
both exhibit deletion polymorphisms. Homozygous deletions of these genes, called 
GSTM1 and GSTT1 null genotyping, results in lack of enzyme activity 
(Gudmundsdottir K. et al. 2000). An A to G polymorphism at nucleotide 313 in the 
GSTP1 gene results in an amino acid substitution (Ile105Val). This residue lies in the 
substrate-binding site of the enzyme and the polymorphism has been shown to affect 
enzyme activity (Gudmundsdottir K. et al. 2000). A decrease in the GSTP1 enzyme 
activity will result in inefficient detoxification of carcinogens and an increase in 
cancer risk. 
The association of GSTM1 null genotype with cancer was observed mostly in bladder 
and lung cancers. However, in some studies, GSTM1 
null genotype was found to be associated with breast 
cancer risk (Table 3). 
The results of association studies between GSTP1 genotype and many cancers 
including breast cancer are discordant in different 
populations (Table 4). 
The GSTT1 null genotype seems to be associated with cancers of the larynx, 
skin, astrocytomas, meningioma, and the myelodysplastic syndrome, but not with 
cancers of the bladder, stomach, liver, ovary or endometrium (Table 5). 
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1.1.3  Genetic Events Outside the Cancer Pathway 
 
Genetic variations may determine the outcome of interactions between exogenous 
carcinogens and the cell. Such gene-environment interaction between exposure to certain 
chemicals and genetic variations may increase cancer risk. Although variations may account 
for large and important differences in cancer susceptibility in the population, information on 
the gene-environment interaction may show us ways of reducing these risks. Tissue specific 
expressions of genes may indicate the relation between the tissue specific genes and exposures 
(Willams JA. 2001). 
 Variations in the circulating levels of growth factors or hormones increase cancer risk. 
It has been shown that prolonged exposure to estrogen is associated with an increased risk of 
developing breast cancer. Therefore, factors that increase the number of menstrual cycles such 
as early age at menarche, nulliparity, and the late onset of menopause increase the probability 
of breast cancer (Michels B. et al. 2001)  
 Several factors influence the evolution of cancer (Figure 4). 
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Figure 4: A framework for genetic events related to cancer development (adopted from 
Ponder BAJ. 2001). 
 
1.2 Breast Cancer 
1.2.1 Clinical Information 
1.2.1.1 Epidemiology and Etiology 
 
 Breast cancer is the most commonly diagnosed cancer among women, after 
nonmelanoma skin cancer. Breast cancer is the second leading cause of cancer deaths after 
lung cancer. In 2002, an estimated 205,000 new cases will be diagnosed and 40,000 deaths 
from breast cancer will occur  in USA (Atlanta GA. 2002). 
  Breast cancer is a complex, multifactorial disease where both genetic and 
environmental factors have important contributions. The cumulative risk of breast cancer 
increases with age with most breast cancers occurring after the age of 50 (Feuer EJ. et al. 
1993). Breast cancer occurs at an earlier age in women with a genetic susceptibility. Breast 
cancer risk increases with early menarche and late menopause, and is reduced by early first 
full term pregnancy. It is reported that these factors influence breast cancer risk only among 
women who did not have a mother or sister with breast cancer (Colditz GA. et al. 1996). 
However, a protective effect has been seen with early age at first live birth, and also with 
parity of 3 or more, in women with known mutations of the BRCA1 gene (Norad S. et al. 
1993, and Norad SA. et al. 1995). The effect of reproductive history can only be explained by 
the contribution of other factors to breast cancer. Several lifestyle factors such as weight gain, 
obesity, fat intake, and level of physical activity are also associated with breast cancer risk. 
Overweight women are most commonly observed to be at increased risk of postmenopausal 
breast cancer and at reduced risk of premenopausal breast cancer that is thought to be estrogen 
related. However, these factors have not been well evaluated in women with a positive family 
history of breast cancer or in carriers of cancer-predisposing mutations. Similarly, alcohol 
consumption and a high-fat diet may be associated with an increased risk. Other risk factors 
may be important in subgroups of women defined according to genotype. For example, 
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polymorphisms of NAT gene have been observed to influence female smokers’ risk for breast 
cancer (Ambrosone CB. et al. 1996).  
 Breast cancer is the most common cancer in females in Turkey (Ozsari H. and 
Atasever L. 1997). The life-time prevalence of the disease ranges between 1 in 8 to 1 in 12 in 
Western populations (Pharoah PD. and Mackay JF. 1998, and National Cancer Institute 1999). 
1.2.2. Genetic Predisposition to Breast Cancer  
 
 Genetic factors influence the development of breast cancer. Females with germ-line 
mutations in BRCA1 or BRCA2 genes have an extremely high risk of developing breast 
cancer, but such strong predispositions are rare. Approximately 10-15% of breast cancer cases 
have a family history of the disease. Germ-line BRCA1 and BRCA2 mutations have been 
identified in approximately 5% of women diagnosed with breast cancer (Claus EB. et al. 
1996, and Ozdag H. et al. 2000). Somatic mutations are absent in BRCA1 and a very low 
frequency of BRCA2 mutations exist in breast cancer cases. Mutations in BRCA1 and BRCA2 
interacting proteins may affect their function. Another gene causing predisposition to very 
rare breast cancer susceptibility is TP53 (Borresen AL. et al. 1992). The most interesting 
polymorphism of the TP53 gene is Arg72Pro polymorphism. Studies on this polymorphism in 
various cancers reveal quite discordant results. The interaction of p53 with p73 is influenced 
by this polymorphism. 
 Other genetic variations confer a low risk to the individual, but are common in a 
population. Weak predisposition to breast cancer may result from genetic variations in cancer 
pathways and low penetrance genes. These polymorphically expressed low penetrance genes 
code for the enzymes that may have a role in the metabolism of estrogens or detoxification of 
drugs and environmental carcinogens. Although the clinical significance in breast cancer is 
unclear, genetic polymorphisms may account for the individual differences in sensitivity to 
carcinogens such as estrogen metabolites. 
 Molecular epidemiology studies of breast cancer have found associations with P450 
cytochrome genotypes such as CYP1A1, CYP2D6, and CYP17 (Table 7). Studies of the NAT2 
genotype and breast cancer susceptibility have shown inconsistent results (Table 6). 
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 Individuals with a polymorphism in the GSTM1, GSTT1 or GSTP1 genes may have a 
higher risk of breast cancer because of their impaired ability to metabolize and eliminate 
carcinogens. Carcinogens such as PAHs, are lipophilic and stored in adipose tissues, including 
breast tissue (Wu F. et al. 2002). The most extensively studied polymorphisms in human 
breast cancer are associated with carcinogen-metabolism (Table 6, and Table 7). 
The results of association studies between GST genotypes and breast cancer are 
discordant in different populations (Rebbeck TR. et al. 1997, Helzlsouer KJ. et al. 1998, 
Ambrosone CB. et al. 1999, and Maugard CM. et al.  2001) despite this neat theoretical 
framework.   
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1.3. Aim 
 
The purpose of this study is to determine whether GSTM1 null, GSTP1 Ile105Val, GSTT1 
null genotypes are genetic susceptibility factors for breast cancer in the Turkish population.  
This study deals with the following questions: 
 
1.    Are Glutathione S-tranferase gene polymorphisms genetic risk factors for breast  cancer in 
the Turkish population? 
2.   Are Glutathione S-tranferase polymorphisms associated with the established risk factors 
for breast cancer? 
 
The GSTM1 locus was included in this study, since negative results have been reported in 
some populations, and no data about GSTM1 polymorphism was available for the Turkish 
population.  
The GSTP1 locus was studied because its role was less established as a breast cancer risk 
factor.   
The GSTT1 and GSTP1 loci were analyzed because no data was available for the Turkish 
population in regard to their association with breast cancer.  
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2. Materials and Methods 
 
2.1. Materials 
 
2.1.1 Subject: 
 Our study population consisted of 264 females previously diagnosed with breast 
cancer, 233 age-matched females and 77 random controls as a control group with no history 
of cancer. Cases and controls consented to participate in this study by giving blood samples 
and personal information. At the time of blood donation, each individual completed a 
standardized questionnaire including data on age, weight, height, menstrual and reproductive 
histories, family history of breast and other cancers (first degree relatives; only mother, sister 
or daughters) and smoking status. 
 A blood sample was collected from each volunteer and DNA extracted using a 
standard procedure as described in section 2.1.2. 
 
2.1.1.1 Patients: 
 264  breast cancer patients were included in the study (Table 8). All patients were 
diagnosed at Hacettepe University Medical School, Ankara, Numune Hospital, and SSK 
Ankara Oncology Hospital, which are located in Ankara and predominantly serve patients 
from central Anatolia. 
 Information about age, weight and height of the patient, age at menarche, age at full 
term pregnancy, number of full term pregnancies, family history of breast cancer, and  
smoking history were obtained from standardized questionnaire forms. Information about the 
histopathology of the tumors, estrogen receptor status, and progesterone receptor status were 
obtained from the medical records (See; questionnaire form) 
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1. Adı Soyadı: 
2. Yaşı: 
3. Medeni Hali: 
4. Yaşadığı şehir ve süresi: 
5. Ağırlığı (kg): 
6. Boyu (cm): 
7. Mesleği: 
8. İlk menstürasyon periyodunun başlama yaşı: 
9. Menapozal durumu: 
 Premenapozal ise; son menstürasyon periyodunun kaç gün önce olduğu: 
 Postmenapozal ise; son menstürasyon periyodunun kaç gün önce olduğu: 
10. Tanı konulduğu zamanki menapozal durumu: 
11. Tanının ne zaman konulduğu: 
12. Uygulanan tedavi: 
13. Daha önce hormon tedavisi gördü mü? Ne tip? 
14. Oral kontraseptif kullandı mı? Nedir? 
15. Kaç çocuğu var? 
 a. İlk doğumunu yaptığı yaş: 
 b. Son doğumunu yaptığı yaş: 
16. Daha önce meme ile ilgili operasyon geçirdi mi? 
17. Ooferektomi (yumurtalıkların alınması) yapıldı mı? Yapıldı ise kaç yıl önce? 
18. Sigara içme alışkanlığı: 
 Hiç içmedim () Eskiden içerdim () 
 1-10 sigara /gün ()  11-20 sigara /gün ()  20 ve daha fazla/gün () 
 1 yıldır içiyorum ()  2-5 yıldır içiyorum ()  5-10 yıldır içiyorum () 
 10-15 yıldır içiyorum()  15-20 yıldır içiyorum ()  20 ve daha fazla yıldır içiyorum () 
17. Sigara içilen ortamda sıkça bulunuyormusunuz? 
  (a) Evet (b) Hayır 
18. Alkol kullanıyormusunuz? 
  (a) Evet (b) Hayır 
 Nadiren Haftada 1 kez  Haftada 2-3 kez Haftada 4-5 kez Haftada 6-7 kez 
19. Beslenme alışkanlığınızda size en fazla uyan tanım aşağıdakilerden hangisidir? 
 (a) Kızartma ağırlıklı yağlı diyet 
 (b) Sebze ağırlıklı yağsız diyet 
 (c) Dengeli beslenme 
20. Radyasyona maruz kaldınız mı? Hangi sıklıkla? 
  (a) Evet (b) Hayır  
21. Tiroid ile ilgili bir rahatsızlığınız var mı? 
  (a) Evet (b) Hayır 
  Hipertiroidizm () Hipotiroidizm () 
22. Aile bireylerinde ve sizde genetik bir rahatsızlık var mı? Tipi. 
  (a) Evet (b) Hayır 
23. Ailenizde meme kanserli başka bireyler var mı? (Anne, kardeş, anneanne, vb.) 
24. Tümörün histopatolojisi 
25. Tümör grade 
26. Tümör stage 
27. Östrojen reseptör durumu (+) veya (-) 
28. Progesteron reseptör durumu (+) veya (-) 
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 2.1.1.2 Age-matched Control Group: 
 233 women from Ankara Numune Hospital and SSK Ankara Oncology 
Hospital (Table 8) were included. Information about the age, weight, height, age at 
menarche, age at full term pregnancy, number of full term pregnancies, family 
history of breast cancer, and smoking history were obtained from standardized 
questionnaire forms. 
 
2.1.1.3 Random Control Group 
 The random control group consisted of 77 students from Bilkent University. 
Information about age and sex were obtained from each individual. 
 
2.1.2 Oligonucleotides: 
 The oligonucleotides used in PCR experiments are given in Table 9. 
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2.1.3 Chemical and Reagents 
Agarose Basica LE, EU 
Boric acid Sigma, St.Louis, MO, USA 
Bromophenol blue Sigma, St.Louis, MO, USA 
Chloroform Carlo Erba, Milano, Italy 
Ethanol Merck, Frankfurt, Germany 
Ethidium bromide  Sigma, St.Louis, MO, USA 
Ficoll Type 400  Sigma, St.Louis, MO, USA 
Gamma Micropor Agarose Prona LE, EU 
Isoamyl alcohol Carlo Erba, Milano, Italy 
Phenol Carlo Erba, Milano, Italy 
Proteinase K Appligene-Oncor, USA 
pUC Mix Marker, 8 MBI Fermentas Inc., NY, USA 
Sodium acetate Carlo Erba, Milano, Italy 
Sodium dodecyl sulfate(SDS) Sigma, St.Louis, MO, USA 
TrisHCl Sigma, St.Louis, MO, USA 
Trisodium citrate Sigma, St.Louis, MO, USA 
Xylene cyanol Sigma, St.Louis, MO, USA 
  
  
44 
2.1.4 PCR Materials 
 Taq polymerase (5U/µl), 10X PCR buffer (100 mM Tris-HCl, pH 8.8 at      25 oC, 500 
mM KCl, 0.8% Nonidet P40), 25 mM MgCl2, 10 mM dNTP mix were obtained from MBI 
Fermentas Inc., NY, USA. 
 
2.1.5. Restriction Endonucleases 
 
 Alw261 restriction endonuclease enzyme was obtained from MBI Fermentas Inc., NY, 
USA. 
 
2.1.6 Standard Solutions 
 
Agarose gel loading buffer (6X) 
15 % ficoll 
0.05 % bromophenol blue 
0.05 % xylene cyanol 
 
DNA Extraction buffer 
10 mM Tris HCl, pH 8.0 
10 mM EDTA, pH 8.0 
0.5 % SDS 
 
Proteinase K (stock); 20 mg/ml 
 
SSC (20X) 
  3 M NaCl 
  0.3 M trisodium citrate, pH 7.0 
 
TE Buffer 
  10 mM Tris HCl pH 8.0 
    1 mM EDTA 
Tris-boric acid-EDTA (TBE) (10 X) (1L) 
  108 g Tris HCl 
  
  
45 
   55 g boric acid 
  20 ml 0.5 M EDTA 
  Complete final volume to 1 L with ddH2O 
 
 
Standard DNA size markers 
 
PUC Mix Marker, 8 (MBI, Fermentas) 
 
 
                                   
 
 
 
2.2 Methods 
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2.2.1 DNA Isolation: 
 
 Peripheral blood was collected in EDTA-containing tubes and stored at 4 oC for a 
period of five days. The blood was then divided into 800 µl aliquots and stored at -20 oC. 
These 800 µl blood samples were used for DNA extraction by standard proteinase K/SDS 
digestion and phenol-chloroform extraction. The blood samples were washed before 
proteinase K/SDS digestion. After the aliquots were thawed 800µl l x SCC was added and 
mixed by vortexing. The samples were then centrifuged at 13,000 rpm for 1 minute. The 
supernatant was carefully removed and discarded into the chloros. The cell pellet was 
resuspended in 1.4 ml l x SSC and centrifuged at 13,000 rpm for 1 minute. This washing step 
was repeated until the pellet became white. The pellet was then resuspended in 800µl DNA 
extraction buffer containing 20µl proteinase K (20 mg/ml) solution. The samples were 
incubated at 56 oC for 4 hours, and were briefly mixed every 20 minutes. If the cell pellet was 
not dissolved completely at the end of this incubation period, the tubes were left overnight at        
56 oC. 
 After the cell pellet was completely dissolved, the phenol/chloroform step was carried 
out in the fume-hood. 400µl phenol/chloroform/isoamylalcohol (25:24:1) was added and the 
tube was vortexed vigorously.  The tube was then centrifuged at 13,000 rpm for 5 minutes. 
The upper aqueous DNA-containing layer (~700 µl) was transferred into a new tube. If the 
DNA supernatant was sticky and not resuspended completely or if interface was not clear the 
extraction step was repeated by adding 350µl phenol/chloroform/isoamylalcohol (25:24:1). 
Then 35µl NaOAc (3mM, pH=5.2) and 700µl ice-cold absolute ethanol (EtOH) were added to 
the upper aqueous layer to precipitate the DNA, mixed by inversion and incubated at -20 oC 
for a duration of 30 minutes to overnight. The tubes were then centrifuged  at 13,000 rpm for 
15 minutes. Afterwards, ethanol was discarded and the pellet air-dried. The pellet was 
solubilized in 200 µl TE (pH 8.0) or in sterile ddH2O by incubation at     56 oC for 1 hour. If 
the pellet was not dissolved completely, overnight incubation at 56 oC was carried out. The 
DNA samples were stored at 4 ºC up to 2 months or at -20 oC for long-term. 
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2.2.2 Polymerase Chain Reaction (PCR) 
 
 The polymerase chain reaction is a method for oligonucleotide primer directed 
enzymatic amplification of a specific DNA sequence of interest.  
All amplification reactions were carried out on a Perkin Elmer 9600 PCR machine. 
 
2.2.3 Restriction Endonuclease Digestion : 
 
 Amplified GSTP1 products were subjected to digestion to analyze A3136 
polymorphism in GSTP1. Enzyme digestion reaction was carried out using 10 µl PCR 
product, 10 x buffer Y+/TANGO (MBI Fermantas) (33 mM Tris-acetate, 10 mM Magnesium 
acetate, 66 mM Potassium acetate, 0.1 mg/ml BSA pH=7.9 at 37 oC),    3 units of Alw26I 
(MBI, Fermentas) in 30 µl reaction volume and the samples were incubated at 37 oC for 4 
hours. 
 
2.2.4  Agarose Gel Electrophoresis : 
 
 Agarose gel electrophoresis was used to analyze the PCR products. 2% (w/v) agarose 
gels were prepared in 1xTAE buffer and 1µl of ethidium bromide solution from 10mg/ml 
stock was added to the buffer. 8µl PCR product was mixed with 1.5µl 6x loading buffer and 
the mix was loaded onto the gel. The products were run at 90 volts for 45 minutes. The gel 
was then analyzed under the transilluminator and photographs were taken. 
 To analyze the restriction fragments, 3% 1:1 ratio of Agarose: Gamma micropore was 
used. 20µl of digested products were mixed with 4µl of 6x loading buffer and the mix was 
loaded onto the gel. Electrophoresis was performed at 90 volts for 30-45 minutes. The gel was 
photographed under UV light. pUCmix8 ( MBI Fermentas) was used as the DNA size marker. 
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2.2.5 Genotyping of Individuals : 
 
 The GSTP1 polymorphism was analyzed by PCR and restriction enzyme digestion for 
genotyping. GSTT1 and GSTM1 genotypes were analyzed by PCR. The genotypes of each 
individual were scored by two independent researchers to eliminate uncertainty. 
 
2.2.5.1 GSTP1 Genotyping 
  
 Ile 105 Val polymorphism in GSTP1 was analyzed by PCR and restriction digestion. 
For GSTP1 PCR amplification, 50-100ng genomic DNA was used in a total of 25µl reaction 
volume containing 10pmol each of GSTP1 primers, 200µM of dNTP mix, 10xPCR buffer, 
1.5mM MgCl2, 1U DNA Taq polymerase. The amplification conditions were as follows; 
initial denaturing step at 94 oC for 5 minutes, followed by 30 cycles of denaturing for 30 
seconds at 94 oC, annealing for 30 seconds at 57 oC, extension for 30 seconds at 72 oC. The 
reaction was completed with a final extension at 72 oC for 7 minutes. The expected 
amplification product, 176bp, was digested with 3 U Alw26I at 37 oC for 4 hours. The 
digested fragments were electrophoresed in 3% 1:1 ratio of Agarose: Gamma Micropore. The 
presence of 91bp and 85bp restriction fragments indicate the presence of Val allele (see 
Figure 5 for schematic representation). 
 
2.2.5.2. GSTT1 Genotyping 
 
 GSTT1 genotyping was determined by PCR using GSTT1 gene specific primers. 
GSTP1 primers were also included in the PCR mixture as a control to see the independent 
amplification of each sample. For GSTT1 PCR genotyping, 50-100ng genomic DNA was used 
in a total volume of 25 µl containing 10 pmol of each GSTT1 primers, 200µM of dNTP, 
10xPCR buffer, 2.0mM MgCl2, and 1U of DNA Taq polymerase. The amplification 
conditions were as follows: initial denaturing step at 94 oC for 5 minutes, followed by 30 
cycles of denaturing for 30 seconds at 94 oC, annealing for 30 seconds at 60oC, extension for 
30 seconds at 72 oC. The reaction was completed with a final extension at 72 oC for 7 
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minutes. The expected amplification product was 138bp in GSTT1 positive individuals. For 
GSTP1 genotyping, reaction conditions were carried out as described previously in Section 
2.2.4.1. Null genotypes were scored after GSTP1 amplifications were confirmed (see Figure 6 
for schematic representation).  
 
2.2.5.3 GSTM1 Genotyping  
 
 GSTM1 genotype was determined by GSTM1 amplification and by CYP2E1 
amplification as an internal control reaction. CYP2E1 primers were also included in the PCR 
mixture as a control to see the independent amplification of each sample. Both reactions were 
carried out in the same reaction tube. GSTM1 PCR genotyping experiments were performed 
by using 50-100ng genomic DNA, 10xPCR buffer, 10 pmol of each GSTM1 primers, 20 pmol 
of each CYP2E1 primers, 200µM dNTP, 1.5 mM MgCl2 in a total volume of 25µl. The 
amplifications were carried out by the following conditions;  94 oC initial denaturation for 5 
minutes followed by 35 cycles of denaturation for 30 seconds at 94 oC, annealing for 30 
seconds at 55 oC and extension for 45 seconds at 72 oC, with a final extension at 72 oC for 7 
minutes. The expected amplification product was 215 bp in GSTM1 positive individuals. The 
412 bp product size for CYP2E1 was expected to be amplified in all samples (see Figure 7 for 
schematic representation). 
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2.2.6 Statistical Analyses 
Statistical analyses were carried out with the Minitab 13.1 software program. 
 
2.2.6.1 Chi-square Test 
 
There are basically two types of random variables yielding two types of data: 
numerical (e.g. number of children) and categorical (e.g. GSTP1 genotype, whose 
values are Ile/Ile, Ile/Val, Val/Val). A chi-square (X2) statistic is used to investigate 
whether distributions of categorical variables differ from one another. The chi-square 
test is also a test of independence; it provides little information about the strength 
(e.g. strong, weak, perfect) or form (e.g. positive, negative) of association between 
two variables (Daniel WW. 1995).  It is a series of mathematical formulas which 
compare the actual observed frequencies (e.g. variable: GSTP1, categories: Ile/Ile, 
Ile/Val, and Val/Val) with the expected frequencies. That is, the chi-square analysis 
tests observes results against the null hypothesis (null hypothesis is the hypothesis to 
be tested) and assesses whether the actual results are different from the expected ones 
(Daniel WW. 1995).  The requirements for the test are: 
 The sample must be randomly drawn from the population.  
 Data must be reported in raw frequencies (not percentages). 
 Any observations must fall into only one category or value on each variable. 
 This test should only be used when observations are independent (e.g. no 
category or response is dependent upon or influenced by another). 
 Observed frequencies can not be too small. For instance, the GSTP1 105 
Val/Val genotype frequency was too low in our population (8.43% in cases and 
8.58% in controls). So, the GSTP1 105 Ile/Val and Val/Val genotypes were 
combined in our study. 
The chi-square test is one of the methods of calculating a P value. The P 
value shows us whether a result is statistically significant.  In other situations, to 
make a decision based on a single comparison, the steps of statistical hypothesis 
testing must be followed: 
 A threshold P value must first be  settled. The threshold value is traditionally 
usually set as 0.05.  
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 The null hypothesis must be defined. If two means are being compared, the 
null hypothesis is that the two populations have the same mean.  
 The chi-square test must be carried out to compute the P value.  
 The P value must be compared to the preset threshold value.  
 If the P value is less than the threshold, the null hypothesis is rejected and the 
difference is statistically significant. 
 If the P value is greater than the threshold, the null hypothesis is not rejected 
and the difference is not statistically significant, and there sufficient evidence is 
not present to reject the null hypothesis.  
 The P value is a probability, with a value ranging from zero to one. If the P 
value is small, it is concluded that the difference is quite unlikely to be caused by 
random sampling, and the populations have different means. 
If a result is statistically significant, there are two possible explanations: The 
populations are identical, so there really is no difference. By chance, larger values in 
one group and smaller values in the other are obtained. Finding a statistically 
significant result when the populations are identical is called making a Type I error. 
If statistically significant is defined to mean "P<0.05", then a Type I error is made in 
5% of experiments where there really is no difference. The other explanation is that 
the populations are really different and that the conclusion is correct (Pagano M. and 
Gauvreau K. 1992). 
If a result is not statistically significant, it is also possible that the study 
missed a small effect due to small sample size and/or large scatter. In this case, a 
Type II error has been made concluding that there is no difference when in fact there 
is a difference (Pagano M. and Gauvreau K. 1992). 
Statistical calculations combine sample size and variability (standard 
deviation) to generate a confidence interval (CI) for the population mean. Intervals 
can be calculated for any desired degree of confidence, but 95% confidence intervals 
are used most commonly. If many 95% CI from many data sets are generated, the CI 
is expected to include the true population mean in 95% of the cases and not to 
include the true mean value in the other 5%. 
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The other most frequent use of chi-square distribution is to test the null 
hypothesis that two criteria of classification are independent when applied to the 
same set of entries. According to two criteria, a table in which the rows (r) represent 
the various levels of one criterion of classification and the columns (c) represent the 
various levels of the second criterion is prepared. Such a table is generally called a 
contingency table. 
Where the null hypothesis is true, chi-square is distributed approximately 
with k-r degrees of freedom.  In determining the degrees of freedom, k is the number 
of the groups for which observed and expected frequencies are available, and r is the 
number of the restrictions or constraints imposed on the given comparison.  For the 
analysis of the contingency tables, in which r rows represent the various levels of one 
criterion, and the c columns represent the various level of a second criterion, degrees 
of freedom are calculated as (r-1)(c-1)=df  (Pagano M. and Gauvreau K. 1992). 
 
2.2.6.2 Odds Ratio Calculation 
 
There are two types of observational studies: prospective and retrospective 
case-control studies. The primary difference between the two is the sampling 
scheme. When sampling is based upon the response variable, the study is called a 
retrospective study. When sampling is based upon the stimulus variable, the study is 
called a prospective study. A prospective study is related to the future.  The subjects 
are stratified according to whether they have the risk factor or not.  The outcome is 
evaluated after a certain follow-up period has passed (e.g. after GST genotyping  
follow-up for 30 years to observe the individuals that will develop breast cancer).  A 
retrospective study is related to past.  The persons with the outcome constitute the 
study group, and whether these subjects have the risk factor or not is determined (e.g. 
find a breast cancer group and control group, determine if they are postmenopausal 
or premenopausal, and then carry out GST genotyping). The retrospective or case 
history studies are relatively quick and inexpensive, easily repeatable and enable a 
larger number of individuals to be examined (Slome C. 1982). The characteristics of 
the disease under study plays a role in determining whether a prospective or 
retrospective study should be employed. The rarer the disease or the longer the 
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interval between the suspected cause and the condition, the more difficult is the 
cohort study. The term relative risk is used for the risk estimation obtained from 
prospective studies.  It is actually the ratio of the risk of developing a disease among 
subjects with the risk factor to the risk among subjects without the risk factor. If the 
data are from a retrospective study, relative risk is not a meaningful measure for 
comparing the two groups. The appropriate test for comparing cases and controls in a 
retrospective study is the odds ratio (Rim AA. 1981). In any event, for rare diseases 
the odds ratio is a close approximation of the relative risk.  
The odds ratio can assume a value between zero and infinity. A value of zero 
is the indicator of no association between the risk factor and disease status. A value 
greater than 1 indicates a higher risk among cases when compared to controls. The 
odds ratio takes a value somewhere between the lower and upper limits of the 
confidence intervals. An odds ratio value greater than 1 is statistically significant, if 
the lower limit of 95% confidence intervals is greater than 1 (Daniel WW. 1995). 
 
Table 10. Sample 2x2 Table for OR analysis 
 
Risk factor 
 
 
Control 
 
Case 
 
Present 
 
 
a 
 
c 
 
Absent 
 
 
b 
 
d 
 
a: number of controls with the risk factor  
b: number of controls without the risk factor  
c: number of cases with the risk factor  
d: number of cases without the risk factor 
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The following formulas are used for odds ratio calculations, and confidence 
intervals: 
 
OR=ad/bc 
 
95% CI= e ln [OR]± 1.96 times square root of (1/A+1/B+1/C+1/D ) 
 
 
2.2.6.3. Multivariate Adjusted Odds Ratio Calculation        
 
To measure the relationship between one interval dependent variable (e.g. 
GSTP1 genotype) and several independent variables (e.g. age, age at menarche, age 
at first full-term pregnancy, number of children, family history of breast cancer) the 
multiple regression test is used. In this analysis, the independent variables can predict 
the dependent variables, but the dependent variables can not be used to predict the 
independent variables.  Independent variables should be justified theoretically.  The 
selected independent variables should have strong correlations with the dependent 
variable but only weak correlations with other independent variables. Each 
independent variable should have the same relationship with the dependent variable 
at each value of other independent variables. Multiple regression modeling is used to 
determine what variables contribute to the explanation of the dependent variable and 
to what degree.  A theoretically well-defined model when applied to analysis, the 
adjusted odds ratio is a valuable statistical tool. 
 
2.2.6.4. Gene-environment, Gene-gene Interaction Analyses 
 
If cases or controls that are being compared differ in any characteristic that is 
related to the disease (in this instance breast cancer) and to the exposure (or potential 
risk factor or cause), then these differences must be taken into account when making 
these comparisons (Dunning MA. et al. 1999). 
A case control study group is designed to investigate the presence of an 
interaction between a genetic and environmental factor. The environmental (E=e) 
and genetic factors (G=g) are binary variables that take values of 1 for exposed (e. 
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high BMI) or susceptible (e.g. the combination of GSTP1 105 Ile/Val or Val/Val 
genotypes), and 0 for unexposed (e.g. low BMI) or not susceptible (e.g. GSTP1 
Ile/Ile). Disease status (D=d) takes a value of 1 for affected (breast cancer patients) 
and 0 for the unaffected (age-matched control) (Garcia-Closas M. et al. 1999). The 
odds ratio OReg  is the measure of association between disease and environmental 
and genetic factors.  
 The multiplicative interaction parameter is Ψ. In the absence of a 
multiplicative interaction, Ψ=1 (Table 11). 
The additive interaction parameter is Φ.  In the absence of an additive 
interaction  Φ=1 (Table 11). 
The odds ratio for the reference group (e.g. 00 individuals) is 1, since the 
odds ratio for this group is calculated by comparing the reference group by itself. The 
odds ratios were calculated by comparing the reference group (the individuals 
inheriting no risk genotypes) to the others respectively.  
For gene-gene interaction (the combined effects of studied genes) analysis, 
the same method can be used. However, that time the environmental (E=e) factor is 
replaced with the genetic factor. These binary variables take values of 1 for both 
susceptible (e.g. GSTM1 null genotype or GSTT1 null genotype), and 0 for both not 
susceptible cases (e.g. GSTM1 positive or GSTT1 positive).  
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  Table 11: Definition of ORs (OR01, OR10, OR11) and interaction parameters 
(Ψa,Φa) for the relations of two dichotomous environmental and genetic factors 
and cancer. 
                   
   Genetic factor (G) 
      
   G = 0  G = 1 
      
  E = 0 1.0a  OR01 
Environmental factor     
  E = 1 OR10  OR11 
      
                                 
          Ψ    = —————— 
 
          
           Φ = ————————— 
 
Raeference category  
 
 
 
 
 
 
OR11 
OR10 . OR01 
 
(OR11 – 1) 
 
(OR10 – 1) + (OR01 – 1) 
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3. RESULTS: 
  
We examined associations for gluthathione S-transferases M1 (GSTM1), T1 
(GSTT1), and P1 (GSTP1) genotypes and breast cancer risk in the Turkish 
population. Genotyping for GSTs was conducted on 264 breast cancer cases and 233 
age-matched controls. A group of randomly selected university students (n=77) was 
also genotyped to compare with the age-matched control group. 
The nucleotide polymorphisms were identified by PCR assays for GSTM1 
and GSTT1 genes. The examples of PCR analysis for GSTM1 and GSTT1 genotyping 
are shown in Figures 8 and 10. GSTP1 polymorphism was identified by restriction 
enzyme site digestion of the GSTP1 PCR product.  An example of the result of this 
genotyping analysis is shown in Figure 9. 
All 264 breast cancer patients and 233 control groups were subjected to 
genotyping analysis, the results were scored and the frequencies of the GSTM1, 
GSTT1, and GSTP1 genotypes were compared. The characteristics of the participants 
in this study have been described in Table 12. The mean age was 49.29 (SD: 13.83, 
range: 20-80) for cases and 46.15 years (SD: 14.11, range: 15-83) for controls, 
contributing to a higher proportion of cases (60.54%) than controls (47.64%) being 
postmenopausal. The mean age was 13.65 (SD: 1.44) at menarche, and 21.78 (SD: 
4.73) at first birth while the mean number of children was 2.95 (SD: 2.16) for the 
cases.  For the control group, the mean age was 13.86 (SD: 1.42) at menarche and 
20.52 (SD: 3.93) at first birth while the mean of number of children was 3.03 (SD: 
2.12).  The mean BMI was 24.48 (SD: 4.72) for the cases and 26.96 (SD: 4.92) for 
the controls. The risk of breast cancer was higher for women who had a BMI ≥ 26.96  
(the mean BMI of controls) (OR= 1.76; 95% CI= 1.23-2.52). The breast cancer risk 
was also higher for postmenopausal cases (OR= 1.69; 95% CI=1.18-2.42). The risk 
of breast cancer was slightly increased for women whose age at menarche was ≤ 12 
(OR= 1.33; 95% CI=0.81-2.18). The risk of breast cancer was 3.80 times higher for 
women who had first-degree relatives with breast cancer (OR= 3.80; 95% CI=1.51-
9.55). There was a slight increased case-control difference in the association between 
high BMI and postmenopausal status in the Turkish population for breast cancer  
(OR= 1.26; 95 % CI=0.77-2.05) (Table 12). 
The distribution of GSTM1, GSTP1, and GSTT1 genotypes in the breast 
cancer patients and age-matched controls by menopausal status, and multivariate 
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adjusted OR stratified according to age, age at menarche, age at full-term pregnancy, 
number of full-term pregnancies, and family history of breast cancer are summarized 
in Table 13. Since the GSTP1 105 Val/Val genotype frequency was too low in our 
population to analyze statistically, GSTP1 105 Ile/Val and Val/Val genotypes were 
combined for cancer risk estimation (Katoh T. et al.  1999). 
 The crude odds ratios were 1.07 (95% CI=0.75-1.52) for the GSTM1 null 
genotype, 1.36 (95% CI=0.95-1.94) for the combined GSTP1 105 Ile/Val and 
Val/Val genotypes and 1.03 (95% C=0.66-1.60) for the GSTT1 null genotypes for all 
subjects. In the premenopausal breast cancer group crude odds ratios were 1.27 (95% 
CI=0.75-2.15) for the GSTM1 null genotype, 1.31 (95% CI=0.77-2.23) for the 
combined GSTP1 105 Ile/Val and Val/Val genotypes, and 1.51 (95% CI=0.75-3.05) 
for the GSTT1 null genotypes. The crude odds ratio of postmenopausal subjects were 
0.92 (95% CI=0.56-1.49) for GSTM1 null genotypes, 1.47 (95% CI=0.89-2.41) for 
the combined GSTP1 105 Ile/Val and Val/Val genotypes, and 0.85 (95% CI=0.46-
1.56) for the GSTT1 null genotype. 
 The adjusted odds ratios were 1.03 (95% CI=0.69-1.55) for the GSTM1 null 
genotype, 1.64 (95% CI=1.09-2.47) for the combined GSTP1 105 Ile/Val and 
Val/Val genotypes, and 1.09 (95% CI=0.65-1.85) for the GSTT1 null genotype when 
premenopausal and postmenopausal breast cancer patients were considered together. 
In the premenopausal breast cancer group adjusted odds ratios were 1.20 (95% 
CI=0.64-2.27) for the GSTM1 null genotype, 2.01 (95% CI=1.06-3.83) for the 
combined GSTP1 105 Ile/Val and Val/Val genotypes, and 1.62 (95% CI=0.66-4.00) 
for the GSTT1 null genotype. Finally, in the postmenopausal breast cancer group 
adjusted odds ratios were 0.75 (95% CI=0.42-1.33) for the GSTM1 null genotype, 
1.50 (95% CI=0.85-2.65) for the combined GSTP1 105 Ile/Val and Val/Val 
genotypes, and 1.04 (95% CI =0.50-2.15) for the GSTT1 null genotype. 
 The odds ratio for all subjects and the premenopausal subjects with the 
combined GSTP1 105 Ile/Val and Val/Val genotypes was increased when the 
multivariate adjustment model was carried out. The multivariate logistic regression 
model stratified odds ratios according to age, age at menarche, age at full-term 
pregnancy, number of full-term pregnancies, and family history of breast cancer.  
According to the model, the combined GSTP1 105 Ile/Val and Val/Val genotypes in 
the premenopausal status were two times or more risky for breast cancer and also the 
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combined GSTP1 105 Ile/Val and Val/Val genotypes for all subjects was found to be 
a significant risk factor for breast cancer.  
 To compare the age–matched control group, randomly selected 77 Bilkent 
University students were genotyped. In the random control group, GSTM1 null 
genotype was 46% (p=0.51), and the GSTT1 null genotype was 17.25% (P=0.57), 
GSTP1 genotype was 67% (Ile/Ile), 31.16% (Ile/Val) and 1.31% (Val/Val) (P=0.27) 
and combined GSTP1 105 Ile/Val and Val/Val genotype was 32.47%. These results 
pointed out that there was no significant difference between the genotype frequencies 
of the age-matched control group and the randomly selected group, so the selected 
age-matched controls were appropriate for the study. The distribution of GST 
genotypes was in Hardy-Weinberg equilibrium in all three groups. 
 The risk of breast cancer from GST genotypes was evaluated by body mass 
index  (kg/m2) that is summarized in Table 14. BMI was dichotomized based on the 
median values (>26.96 kg/m2) for controls (Mitrunen K. et al. 2001). Among women 
with a high BMI, it was shown that a significantly increased risk of breast cancer was 
associated with the combined GSTP1 105 Ile/Val or Val/Val genotypes (OR=2.12; 
95% CI=1.35-3.62). There was also a significantly increased risk present among 
premenopausal women with the combined GSTP1 105 Ile/Val and Val/Val 
genotypes (OR=2.14; 95% CI=0.97-4.70) and the postmenopausal women with the 
GSTP1 105 Ile/Val and Val/Val genotypes (OR=2.16; 95% CI=1.14-4.09). 
 Although the combined GSTP1 105 Ile/Val and Val/Val genotypes was 
shown to be a significant risk factor for breast cancer, when the two genotypes’ 
relative risks were combined (combined analysis of GSTT1 null genotypes with the 
combined GSTP1 105 Ile/Val or Val/Val genotypes) the results indicated that there 
was no increase of risk (OR=0.69; 95% CI=0.35-1.38) (Table 15). The combined 
analysis of GSTM1 null genotype and the GSTP1 105 Ile/Val or Val/Val genotypes 
was also carried out. Table 16 reveals that the risk for breast cancer did not increase 
by combination of the relative risks of both genotypes (OR =1.39; 95 % CI=0.85-
2.28). 
The risk association for the combination of three GST risk genotypes was 
then analyzed. The reference group was designated as GSTM1 and GSTT1 present 
genotypes and the GSTP1 Ile105Ile genotype. Combinations of three risk genotypes 
did not reveal a significant relative risk (OR=0.95; 95 % CI=0.37-2.43) (Table 17).
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 4.DISCUSSION: 
 
It has been suggested that up to 80% of human cancers arise as a consequence 
of environmental exposure (Doll R. et al. 1981). The first line of defense against 
cancer is provided by the ability of the organism to metabolize and detoxify 
endogenous toxins (Smith G. et al. 1995). Therefore, inherited capacity for these 
metabolic activation and/or detoxification reactions may regulate individual 
susceptibility to environmentally induced diseases such as cancer. GSTs are a super-
family of enzymes that are potentially important in regulating susceptibility to cancer 
because of their ability to metabolize reactive electrophilic intermediates to usually 
less reactive and more water soluble glutathione conjugates (Hayes JD. et al. 1995). 
It has been postulated that polymorphisms in enzymes involved in carcinogen 
metabolism increase the risk of cancer in some individuals. The GSTM1 and GSTT1 
genes both exhibit deletion polymorphisms, and homozygous deletions of these 
genes, called GSTM1 and GSTT1 null genotypes, result in a lack of enzyme activity 
(Pemble S. et al. 1994, and Seidegard J. et al. 1988). An A to G polymorphism at 
codon 105 in the GSTP1 gene results in an amino acid substitution (Ile105Val). This 
residue lies in the substrate binding site of the enzyme and the polymorphism has 
been shown to affect enzyme activity (Gudmundsdottir K. et al. 1997). A decrease in 
GST enzyme activity could result in inefficient detoxification of carcinogens which 
could lead to genetic damage and increased cancer risk.  
 It is not yet clear whether the GST polymorphisms affect breast cancer risk. 
To observe the effects of those polymorphisms on breast cancer, GSTM1, GSTP1 and 
GSTT1 polymorphisms were analyzed in 264 female breast cancer patients and 233 
age-matched controls. When the cases and the controls were compared a statistically 
significant association was observed only for the GSTP1 105 Ile/Val or Val/Val 
genotypes (OR= 1.64; 95% CI=1.09–2.47) for all women, and for the premenopausal 
breast cancer patients (OR=2.01, 95% CI=1.06–3.83), which means that 
premenopausal cases with the GSTP1 105 Ile/Val or Val/Val genotype had two or 
more times risk for breast cancer. The significant association of GSTP1 105 Ile/Val 
or Val/Val genotypes with a high BMI (OR= 2.12, 95% CI=1.35–3.62) was shown in 
this study, but not with a low BMI (OR= 0.78; 95% CI= 0.45–1.34) and also the 
same significant association was observed when the women were grouped as 
  
 73 
 
premenopausal (OR=2.14; 95% CI=0.98–4.70) or postmenopausal (OR=2.16; 95% 
CI=1.14–4.09). The analysis of the GSTM1 null genotype and the GSTP1 105 Ile/Val 
or Val/Val genotype interaction and also the GSTT1 null genotype and the GSTP1 
105 Ile/Val or Val/Val genotype interaction revealed that no possible statistically 
significant interaction is present  for these genes (OR=1.39; 95% CI=0.85-2.28 for 
GSTM1 and GSTP1 combined effect) and (OR= 0.69; 95% CI= 0.35-1.38 for GSTT1 
and GSTP1 combined effect).  
 The risk association with the combined risk genotypes of all three GST genes 
was investigated. There was no statistically significant association for the three high 
risk genotypes, GSTM1 null genotype, GSTP1 105 Ile/Val or Val/Val ge notype, and 
the GSTT1 null genotype, (OR= 0.95; 95% CI= 0.37-2.43). 
 Our observation of the lack of association between breast cancer and GSTM1 
or GSTT1 null genotypes is in parallel with studies conducted on Australian (Curran 
JE et al.  2000), French (Maugard CM. et al. 2001), US  Caucasian (Ambrosone CB. 
et al. 1995) and US mixed (Bailey LR. et al. 1998) populations. However, our 
observation contradicts the positive results that have been observed in French 
(Charrier J. et al. 1999), US mixed (Helzlouser KJ. et al. 1998), Korean (Park SK. et 
al. 1993) and Finn (Mitrunen K. et al. 2001) populations. In our study, we found a 
positive association between the combined GSTP1 105 Ile/Val or Val/Val genotypes 
in all women and particularly in premenopausal women and breast cancer in the 
Turkish population. This  result appears to be unique except for a US mixed 
population study  (Helzlsouer KJ. et al. 1998) in which postmenopausal breast cancer 
patients were found to be at higher risk in the presence of the GSTP1 105 Ile/Val or 
Val/Val genotypes.  
 The combination of the GSTM1 null and the GSTP1 105 Ile/Val or Val/Val 
genotypes and also the combination of the GSTT1 null genotype and the GSTP1 105 
Ile/Val or Val/Val genotypes does not lead to any increased risk for breast cancer 
when compared with the combination of the lower risk genotypes of these genes 
(Table 13 and  Table 14). However, the analysis of a Japanese population for lung 
cancer (Kihara M. and Noda K. 1999) and a USA population for breast cancer  
(Helzlouser KJ. et al. 1998)  showed an increased risk for the combination of the 
high risk genotypes of the GSTM1 and the GSTP1 genes. The analysis of the GSTM1 
and GSTP1 loci, in a study from Germany for bladder cancer, found no significant 
association for an increased risk (Steinhoff C. et al. 2000).  
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 The risk associated with the combination of the risky genotypes of all three 
loci was further analyzed and no statistically significant increased risk association 
was observed. However, the analysis of a Finnish population for breast cancer 
showed an increased risk for combination of high risk genotypes of the GSTP1, 
GSTM1 and GSTT1 genes (Mitrunen K. et al. 2001). 
 The estimation of joint effects for GST genotypes and BRCA1 or BRCA2 
status was not carried out because of the predicted small number of BRCA1 carriers 
in the population, and the prediction of BRCA1 carrier number was due to family 
history of breast cancer of the cohort, that information was supplied by the 
questionnaire forms. The increased for breast cancer risk was observed (3.8 times or 
more) when stratification according to family history of breast cancer was carried out 
in our study population (OR= 3.80; 95% CI= 1.51-9.55),(Table 12).  
 The differences in the outcomes of the studies conducted may partly be due to 
differences in the populations studied and of differences in their exposures to the 
agents that are relevant to the development of breast cancer. Population 
heterogeneity is an important issue for the Turkish population and an independent 
random control cohort was genotyped to test for that issue. It was shown that 
genotype distributions of the age-matched control group and the randomly selected 
group were not statistically different. The genotype distributions of the age-matched 
and the randomly selected controls were compared with the previously reported 
Turkish population results (Oke B. et al. 1998, Toruner GA. et al. 2001) by 
employing homogeneity test (Daniel WW. 1995), and it was shown that none of the 
GST loci differ significantly. 
 It is well understood that one of the most important risk factors for 
developing breast cancer is a family history of the disease. However, many non-
genetic risk factors contribute to disease etiology. They can be categorized as 
hormonal and nonhormonal risk factors. As for the environmental exposures, 
smoking history did not modify the effect of GST genotypes as a risk for breast 
cancer. The information about smoking history of our cohort was missing, however, 
stratification with the smoking status of known subjects gave no risk assessment 
related to smoking for breast cancer in consistency with most of the earlier studies 
(Helzlsouer KJ. et al. 1998, Kelsey KT. et al. 1997, and Garcia – Closas et al. 1999). 
Non-hormonal risk factors include exposure to ionizing radiation, alcohol 
consumption and certain dietary factors such as high dietary fat and “well-done” 
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meat (Wynder EL. et al. 1997 and Zheng W. et al. 1998). Evidence for non-
hormonal risk factors for developing breast cancer is controversial due to study bias, 
discrepant data and the inherent difficulties associated with obtaining dietary 
exposure histories (Martin AM. and Weber BL. 2000). A history of alcohol 
consumption or exposure to ionizing radiation data were not available for our study 
group.  
Estrogen exposure is a well-documented risk factor for breast cancer. A 
prolonged or increased exposure such as early age at menarche, nulliparity, and late 
onset of menopause is associated with increased risk. In our study, the cohort was 
analyzed for established breast cancer risk factors. Compared to controls, cases were 
slightly older and more likely to have a family history of breast cancer among first-
degree relatives. Cases had slightly earlier age at menarche, later age at first live 
birth, less number of children, and most of the cases were  postmenopausal.  
 There is an association between obesity and increased risk for breast cancer 
(Ursin  G. et al. 1997). The major source of estrogen in postmenopausal women is 
from the conversion of androstenedione to estrone by adipose tissue, thus obesity is 
associated with a long-term increase in estrogen exposure. According to our analysis, 
the risk of breast cancer was increased for women who had a high BMI (≥ 26.96) 
(OR= 1.76; 95% CI= 1.23-2.52). There was a slight increased case-control difference 
between high body mass index and postmenopausal state in the Turkish population 
for breast cancer  (OR= 1.26; 95% CI= 0.77- 2.05). These observations are consistent 
with premenopausal observations and the direct association of body mass index with 
the increased breast cancer risk of postmenopausal women (Chu SY. et al. 1991, 
Brinton LA. et al. 1992,  Radiner K. et al. 1993, and Franceschi S. et al. 1996). 
Interestingly, in our study, it was shown that high body mass index contributed to 
higher breast cancer risk in relationship to the combined GSTP1 105 Ile/Val or 
Val/Val genotype regardless of the menopausal status. The women with more fat 
tissue might be exposed to a continuous source of carcinogens, since adipose tissue 
stores toxins, and stored toxins might serve as a continuous source of carcinogens 
(Kohlmeier L. et al. 1995). The GSTP1 Ile105Val substitution is located near the 
substrate binding site of the enzyme and the polymorphism has been shown to affect 
the enzyme’s activity (Gudmundsdottir K. et al. 1997). A decrease in GSTP1 enzyme 
activity might result in inefficient detoxification of high amounts of carcinogens 
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deposited in adipose tissues of women with high body mass index which could lead 
to genetic damage and increased breast cancer risk. 
To our knowledge, this is the first genetic study on the associations of GSTs 
with breast cancer in the Turkish population. Our findings support the role for the 
GSTP1 105 Ile/Val or Val/Val genotypes in the development of breast cancer in 
women, especially in premenopausal women and women with high BMI. 
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5. Conclusion and Future Perspectives 
 
Our study provided the following data: 
 
1. GSTP1 Ile105Val polymorphism but not GSTM1 null and GSTT1 null is a 
genetic susceptibility factor for breast cancer, especially for premenopausal 
cases. However, the combination of the studied polymorphisms of GSTM1 
and GSTP1; or GSTT1 and GSTP1; and all three loci do not cause a 
substantial risk. 
2. Traditionally important risk factors for developing breast cancer such as 
family history of breast cancer, earlier age at menarche, high body mass 
index, and postmenopausal state contributed to a higher breast cancer risk in 
the Turkish population. 
3. The combined analysis of high body mass index and the studied genes 
revealed that GSTT1 and GSTM1 null genotypes do not interact with a high 
body mass index.  However, if individuals with a high body mass index carry 
the combined GSTP1 105 Ile/Val or Val/Val genotypes their relative risk 
compared to lean individuals is considerably increased. 
 
The unmeasured genetic and enviromental factors that interact with GSTs 
could also contribute to differences in results across epidemiological studies.  
Further studies, including more genotyping, mutation screening and gene 
expression studies may give us a better understanding of the effects of these 
genetic variations.  
Studies on better defined groups can evaluate the relationship between GST 
polymorphisms and breast cancer pathological staging.  Polymorphisms in other 
genes, which may have important roles in the cellular pathways can also be 
studied and the combined effect of their interaction with the GST genes and with 
each other on an individual’s breast cancer risk can be determined.  The analysis 
of a large number of DNA variations (polymorphisms and mutations) on a 
genome-wide scale can be carried out with oligonucleotide microarray-based 
technologies. 
The possible effect of GST polymorphisms on DNA damage and the 
frequency of mutation in cancer-related genes can be analyzed in relation to other 
factors, most notably the possible modifying effects on the risk associated with 
germ-line mutations in the BRCA genes. 
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